Pharmaceuticals, Biotechnology and Life Sciences
Keytruda/lenvima combination treatment has been approved for certain patients with advanced endometrial carcinoma which isn’t Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR)
Biodesix’s positive Results from Multiple Studies Support Clinical Utility of VeriStrat Testing
Graybug Vision has kicked off second phase of testing microparticle depot formulation of sunitinib malate for intravitreal (IVT) injection (GB-102) in patients with macular edema (ME) secondary to diabetic ME or retinal vein occlusion (RVO).
Lupus Nephritis
Versantis has closed a series B financing round, and plans to use the funds to fuel the completion of ongoing Phase 1b studies with VS-01 and advance its clinical development up to clinical proof-of-efficacy (phase 2a) in 2 indications.
Glenmark Pharmaceuticals won Orphan Drug Designation from USFDA to its bispecific antibody candidate GBR 1342 for the treatment of patients with multiple myeloma who have received prior therapies.
STAMFORD, Conn.–(BUSINESS WIRE)–Purdue Pharma L.P. today announced that it has reached an agreement in principle on a framework for settling the U.S. opioid litigation facing the Company with 24 state attorneys general, analogous officials from 5 U.S. territories, the Plaintiffs’ Executive Committee in the multidistrict litigation (MDL), and co-lead counsel in the MDL.
DALLAS–(BUSINESS WIRE)–The Food and Drug Administration (FDA) has awarded Perspectum Inc $250,000 to qualify its proprietary biomarkers for NASH in…
Schreiner MediPharm has launched a new tamper-evident security concept for luer-lock syringes: Cap-Lock features a combination of a cap adapter and label that firmly seals prefilled syringes and reliably indicates any first opening.
The Janssen has filed for a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking first-in-class approval of guselkumab brand Tremfya, for the treatment of adult patients with active psoriatic arthritis (PsA), and expects to submit a marketing application to the European Medicines Agency seeking approval of TREMFYA as a treatment for PsA before the end of the year.